Mirati Therapeutics | Les Charges D'Exploitation



Les Charges D'Exploitation Changement Date
Agios Pharmaceuticals USD 141.54M 11.8M 2025-12
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
Amgen USD 5.9B 773M 2025-12
Astellas Pharma JPY 436.66B 16.75B 2025-12
AstraZeneca USD 12.53B 4.16B 2025-12
Bayer EUR 10.2B 523M 2025-09
BioCryst Pharmaceuticals USD -387.89M 33.7M 2025-09
Bristol-Myers Squibb USD 8.3B 10.25B 2025-12
Eisai JPY 199.9B 16.22B 2025-12
Eli Lilly USD 10.31B 1.09B 2025-12
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 316.9M 4.69M 2025-09
J&J USD 18.97B 2.38B 2025-12
Merck USD 10.16B 558M 2025-12
Moderna USD 1.54B 259M 2025-12
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Novartis USD 9.86B 115M 2025-09
Pfizer USD 12.91B 79.89B 2025-12
Puma Biotechnology USD 49.26M 3.2M 2024-06
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 462.23M 33.28M 2025-09
Takeda JPY 1.02T 400.98B 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12


Mirati Therapeutics Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.